# Lantus Versus NPH: Comparison in Insulin Naive People Not Adequately Controlled With at Least One Oral Anti Diabetics (OAD) Treatment

> **NCT00949442** · PHASE4 · COMPLETED · sponsor: **Sanofi** · enrollment: 708 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** Insulin Glargine (HOE901) [Lantus]
- **DRUG:** Glimepiride
- **DRUG:** human insulin [NPH]

## Key facts

- **NCT ID:** NCT00949442
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-07
- **Primary completion:** 2012-07
- **Final completion:** 2012-07
- **Target enrollment:** 708 (ACTUAL)
- **Last updated:** 2012-08-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00949442

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00949442, "Lantus Versus NPH: Comparison in Insulin Naive People Not Adequately Controlled With at Least One Oral Anti Diabetics (OAD) Treatment". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00949442. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*